Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T13:45:21.683Z.
Calculation as of: 2026-10-06T13:45:21.683Z.
Quote observation: 2026-10-06T13:39:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2d634a7ba4b3af29dc0bd0f7aeccfce6021194a57d8f55324c803ee9ac920cb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$5.47M
EV/Sales Ratio
0.78x
TTM Avg
1.63x
3Y Avg
1.96x
5Y Avg
36.60x
Market Cap
$5.40M
EV/Sales Ratio
174.36x
TTM Avg
289.54x
3Y Avg
289.54x
5Y Avg
289.54x
Market Cap
$5.25M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.97M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.04M
EV/Sales Ratio
56.77x
TTM Avg
59.29x
3Y Avg
19360.66x
5Y Avg
791152.03x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.59M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.47M | 0.78x | 1.63x | 1.96x | 36.60x |
| Alzamend Neuro Inc (ALZN)vs › | $5.48M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.38M | N/A | 21.78x | 80.72x | 86.37x |
| Lucyd, Inc (LUCY)vs › | $5.83M | 1.00x | 0.52x | 1.80x | 5.65x |
| Lunai Bioworks Inc. (LNAI)vs › | $5.40M | 174.36x | 289.54x | 289.54x | 289.54x |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.25M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.97M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.04M | 56.77x | 59.29x | 19360.66x | 791152.03x |
| Femasys Inc. (FEMY)vs › | $6.07M | 4.09x | 8.87x | 13.46x | 13.63x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
